Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel versus docetaxel + DOXIL/CAELYX in advanced breast cancer
2004-000617-19Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jul 2004
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in breast cancer comparing Docetaxel monotherapy with Docetaxel + DOXIL/CAELYX (2 arms). Primary endpoint: Overall survival. Started Jul 2004; status: completed.
02
Drugs
docetaxelpegylated liposomal doxorubicindoxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-000617-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000617-19.